
Tango Therapeutics (TNGX) Stock Forecast & Price Target
Tango Therapeutics (TNGX) Analyst Ratings
Bulls say
Tango Therapeutics is making significant progress in their development of PRMT5 inhibitors, with upcoming catalysts and positive data updates expected in the second half of 2026. Their partnerships with Revolution Medicines and Erasca provide a strong competitive advantage in the crowded KRAS inhibitor market and a clear path to market for their lead candidate vopimetostat. While there is competition in the PRMT5 space, Tango's differentiated safety profile makes them well-positioned for success. The potential for a partnership or acquisition by Revolution Medicines adds further upside to the stock. However, investors should also be aware of dilutive financing options and potential risks associated with debt offerings that may arise as the company continues to fund its operations.
Bears say
Tango Therapeutics is a promising biotechnology company focused on developing precision oncology therapies for the treatment of cancer, specifically non-CNS and CNS cancers. However, their success is largely dependent on the success of their lead asset, TNG462, and potential competition from other PRMT5 inhibitors, such as Bristol Myers' navlimetostat and Amgen's anvumetostat. Additionally, delays in advancing pipeline candidates, failure to achieve favorable clinical results, and potential FDA delays or issues could pose further risks to achieving their market value and price target. Furthermore, the competitive nature of the oncology market and emerging drugs targeting new mechanisms could also impact their potential for revenue and growth. Ultimately, the current outlook for Tango Therapeutics' stock is negative due to these potential risks and uncertainties.
This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Tango Therapeutics (TNGX) Analyst Forecast & Price Prediction
Start investing in Tango Therapeutics (TNGX)
Order type
Buy in
Order amount
Est. shares
0 shares